• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer
【24h】

Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer

机译：肿瘤靶向纳米结构脂质载体共递送紫杉醇和吲哚菁绿用于激光触发的癌症协同治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A mono approach to cancer therapy usually fails to achieve satisfactory results due to its limited killing effect. Nanostructured lipid carriers (NLCs) with high biocompatibility as well as tumor targetability were successfully designed and formulated in our study to co-deliver paclitaxel (PTX) and indocyanine green (ICG) for combined chemo and photodynamic therapy. ICG not only acted as an imaging reagent but also as a laser responsive agent to aid accelerated drug release under laser irritation. It has been demonstrated that our drug delivery system (DDS) not only significantly enhanced the stability of drugs, produced sufficient local ROS and triggered accelerated drug release upon laser irradiation, but also increased intracellular uptake of drugs and induced increased cytotoxicity in cancer cells via synergistic effects. Moreover, NLCs demonstrated excellent tumor targetability in tumor-bearing mice. Therefore, tumor targeted co-delivery of PTX and ICG mediated by NLCs could be a promising approach for further development as an effective strategy for cancer therapy.
机译：由于其有限的杀伤作用，单一的癌症治疗方法通常无法获得令人满意的结果。在我们的研究中，成功​​设计并配制了具有高生物相容性和肿瘤靶向性的纳米结构脂质载体（NLC），以共同递送紫杉醇（PTX）和吲哚菁绿（ICG）进行化学和光动力联合治疗。 ICG不仅充当成像试剂，而且充当激光响应剂，以帮助在激光刺激下加速药物释放。已经证明，我们的药物递送系统（DDS）不仅显着增强了药物的稳定性，产生了足够的局部ROS，并在激光辐照后触发了加速的药物释放，而且还增加了细胞对药物的吸收并诱导了癌细胞的细胞毒性增加。 >通过的协同作用。此外，NLCs在荷瘤小鼠中显示出极好的肿瘤靶向性。因此，由NLC介导的PTX和ICG的肿瘤靶向共递送可能是作为癌症治疗的有效策略进行进一步开发的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号